PD0325901 | MEK/ERK Pathway Inhibitor | STEMCELL Technologies
PD0325901 is a selective, cell permeable inhibitor of the MEK/ERK pathway that inhibits the activation and downstream signaling of MEK. It is an extremely potent inhibitor, suppressing the phosphorylation of ERK in C26 cells at very low concentrations (IC₅₀ = …
Mirdametinib (PD0325901) | MEK Inhibitor - MedChemExpress
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis.
Mirdametinib (PD0325901) | 99.99%(HPLC) | MEK inhibitor
Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2. PD0325901 shows higher permeability than …
- Reviews: 776
PD 0325901 | MEK | Tocris Bioscience
PD 0325901 is a potent MEK1 and MEK2 inhibitor. PD 0325901 inhibits MEK activity in mouse colon 26 cells (IC 50 = 0.33 nM). PD 0325901 inhibits the growth of melanoma cell lines in vitro and in vivo; induces G 1 -phase cell cycle arrest and apoptosis in a mouse xenograft model.
- Reviews: 7
PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 …
In this study, PD0325901, an oral potent ERK inhibitor, strongly enhanced the efficacy of PD-1 antibody in vitro and in vivo models in non-small cell lung carcinoma (NSCLC) cells.
The biological profile of PD 0325901: A second generation analog …
Apr 1, 2004 · Based on its highly specific inhibition of MEK and its overall pharmaceutical profile, PD0325901 has the potential to provide ultimate validation of MEK as an anticancer drug target. Phase 1 trials with this agent are underway.
MIRDAMETINIB - New Drug Approvals
Jul 31, 2021 · SpringWorks Therapeutics (a spin out of Pfizer ) is developing mirdametinib, a second-generation, non-ATP competitive, allosteric MEK1 and MEK2 inhibitor derived from CI-1040, for treating type 1 neurofibromatosis (NF1) and advanced solid tumors. In June 2021, a phase I/II trial was initiated in patients with low grade glioma. PATENT. US-11066358.
StemMACS™ PD0325901 - Miltenyi Biotec | USA
StemMACS™ PD0325901 is a selective small molecule inhibitor of MEK (mitogen-activated protein kinase, MAPK/ERK kinase), a key component of the Ras/Raf/MEK/ERK signaling pathway. PD0325901 is a derivative of the MEK inhibitor CI-1040 and shows improved cell permeability and higher potency towards ERK1/2 (IC50=0.33 nM).
PD 0325901 | MEK Inhibitors: R&D Systems
PD 0325901 is a potent MEK1 and MEK2 inhibitor. PD 0325901 inhibits MEK activity in mouse colon 26 cells (IC 50 = 0.33 nM). PD 0325901 inhibits the growth of melanoma cell lines in vitro and in vivo; induces G 1 -phase cell cycle arrest and apoptosis in a mouse xenograft model.
InSolution MEK1/2 Inhibitor III, PD0325901 - MilliporeSigma
PD0325901 ≥95% (HPLC), liquid, MEK1/2 inhibitor, Calbiochem® CAS Number: 391210-10-9; Synonyms: InSolution MEK1/2 Inhibitor III, PD0325901,PD 0325901, N-((2R)-2,3 ...